Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1931-2253|26|19|28-30

ISSN： 0959-6682

Source： PRESCRIBER, Vol.26, Iss.19, 2015-10, pp. : 28-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD‐1 and AWARD‐3 clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 896-903

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite